Autologous anti-GD2 CAR T cells efficiently target primary human glioblastoma

• Published in: NPJ precision oncology Vol. 8; no. 1; p. 26
• Main Authors: Chiavelli, Chiara, Prapa, Malvina, Rovesti, Giulia, Silingardi, Marco, Neri, Giovanni, Pugliese, Giuseppe, Trudu, Lucia, Dall’Ora, Massimiliano, Golinelli, Giulia, Grisendi, Giulia, Vinet, Jonathan, Bestagno, Marco, Spano, Carlotta, Papapietro, Roberto Vito, Depenni, Roberta, Di Emidio, Katia, Pasetto, Anna, Nascimento Silva, Daniela, Feletti, Alberto, Berlucchi, Silvia, Iaccarino, Corrado, Pavesi, Giacomo, Dominici, Massimo
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.02.2024; Nature Publishing Group; Nature Portfolio
• Subjects: 631/67/1059/2325; 692/4028/67/1922; Brain cancer; Brief Communication; Cancer Research; Cells; Cytokines; Epidermal growth factor; Gene Therapy; Human Genetics; Immunotherapy; Internal Medicine; Lymphocytes; Medicin och hälsovetenskap; Medicine; Medicine & Public Health; Metabolism; Neurosciences; Neurosurgery; Oncology; Spheroids; Italy
• ISSN: 2397-768X; 2397-768X
• DOI: 10.1038/s41698-024-00506-z

Glioblastoma (GBM) remains a deadly tumor. Treatment with chemo-radiotherapy and corticosteroids is known to impair the functionality of lymphocytes, potentially compromising the development of autologous CAR T cell therapies. We here generated pre-clinical investigations of autologous anti-GD2 CAR T cells tested against 2D and 3D models of GBM primary cells. We detected a robust antitumor effect, highlighting the feasibility of developing an autologous anti-GD2 CAR T cell-based therapy for GBM patients.